Paul-Henri Lambert

Direttore/Membro del Consiglio presso Hookipa Biotech AG

85 anni

Health Technology

Miscellaneous

Consumer Services

Profilo

Paul-Henri Lambert is currently the Director of the International Advanced Vaccinology Course at the University of Geneva.
He also holds the position of Director of the International Advanced Vaccinology Course at Fondation Mérieux.
Additionally, he serves as a Member of the Supervisory Board at Hookipa Biotech AG.
Previously, he worked as the Director at HOOKIPA Pharma, Inc. from 2011 to 2019.

Posizioni attive di Paul-Henri Lambert

Società	Posizione	Inizio
Hookipa Biotech AG Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria.	Direttore/Membro del Consiglio	-
Fondation Mérieux	Corporate Officer/Principal	14/11/2013
University of Geneva	Corporate Officer/Principal	-

Tutte le posizioni attive di Paul-Henri Lambert

Precedenti posizioni note di Paul-Henri Lambert

Società	Posizione	Fine
HOOKIPA PHARMA INC.	Direttore/Membro del Consiglio	25/04/2019

Vedi nel dettaglio l'esperienza di Paul-Henri Lambert

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Paul-Henri Lambert

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
HOOKIPA PHARMA INC.	Health Technology

Aziende private	2
Hookipa Biotech AG Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria.	Health Technology
Fondation Mérieux	Miscellaneous